### Panel Discussion

**KID-3 and KID-4**

**Internal request:**
Panel discussion comment for the inclusion of chemotherapy options "gemcitabine + doxorubicin" and "gemcitabine + capecitabine" for predominant clear cell RCC with predominant sarcomatoid features and "gemcitabine + capecitabine" for non-clear cell RCC with predominant sarcomatoid features.

Based on the data in the noted references, the panel consensus was to add "gemcitabine + doxorubicin" and "gemcitabine + capecitabine" for predominant clear cell histology with predominant sarcomatoid features and "gemcitabine + capecitabine" for non-clear cell histology with predominant sarcomatoid features. These regimens were added as category 2A recommendations.

**References**


**KID-4**

**Internal request:**
Panel discussion comment for the inclusion of cytotoxic chemotherapy regimens "carboplatin + gemcitabine" and "carboplatin + paclitaxel" for collecting duct or medullary subtypes.

Based on the data in the noted reference, the panel consensus was to add the cytotoxic chemotherapy regimen "carboplatin + gemcitabine" for collecting duct or medullary subtypes.

The panel consensus was to add the cytotoxic chemotherapy regimen "carboplatin + paclitaxel" for collecting duct or medullary subtypes.

**References**
